Food and Drug Administration, HHS.
Notification of preemption review.
The Food and Drug Administration (FDA) is announcing that it has determined, after conducting a review of its existing regulations issued within the past 10 years that contain statements in regulatory preambles or codified provisions intended by the Agency to preempt State law, that three FDA regulatory preambles contain or refer to statements about preemption that are not legally justified. FDA conducted this review in response to the President's May 20, 2009, “Memorandum for the Heads of Executive Departments and Agencies,” which outlined the Administration's policy on preemption, in keeping with the principles in Executive Order 13132 on Federalism. The President's memorandum included a directive that such a review be conducted. FDA is also taking this opportunity to clarify certain preamble statements related to preemption resulting from express preemption provisions in the Federal Food, Drug, and Cosmetic Act (FD&C Act) concerning nonprescription drugs and food labeling.
Effective October 5, 2011.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Catherine Lorraine, Office of Policy, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 4258, Silver Spring, MD 20993, 301-796-4830.End Further Info End Preamble Start Supplemental Information
On January 24, 2006 (71 FR 3922), FDA published a final rule entitled “Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products” (physician labeling rule). In the preamble to the physician labeling rule, FDA discussed its views on the preemptive effect of both the regulation's codified provisions and, more generally, the FD&C Act. In addition, FDA subsequently published two final rules with preambles that referenced the preemption discussion in the physician labeling rule. See “Exceptions or Alternatives to Labeling Requirements for Products Held by the Strategic National Stockpile” (72 FR 73589, 73595, December 28, 2007); “Supplemental Applications Proposing Labeling Changes for Approved Drugs, Biologics, and Medical Devices” (73 FR 49603, 49605-49606, August 22, 2008).
In its decision in Wyeth v. Levine, the Supreme Court addressed the preamble to the physician labeling rule and provided additional guidance in evaluating the preemptive effect of the FD&C Act and FDA regulations. 129 S. Ct. 1187 (2009). In this case, the Court upheld a State tort claim that was based on the manufacturer's failure to provide adequate warnings on the labeling of one of its prescription drug products. The Court held that the State claim was not preempted by the FD&C Act or FDA's labeling requirements, despite the Agency's position in the preamble to the physician labeling rule that such claims frustrate its statutory mandate.
According to the Court, FDA's position “does not merit deference,” in part, because it is “at odds with what evidence we have of Congress' purposes.” Id. at 1201. The Court found that Congress's “silence on the [preemption] issue, coupled with its certain awareness of the prevalence of state tort litigation, is powerful evidence that Congress did not intend FDA oversight to be the exclusive means of ensuring drug safety and effectiveness.” Id. at 1200. While the Court acknowledged that “some state-law claims might well frustrate the achievement of congressional objectives,” it found that “failure-to-warn claims” such as the one at issue do not “obstruct the federal regulation of drug labeling.” Id. at 1204. The Court also noted that the manufacturer did not avail itself of FDA regulations that permit changes to a drug's labeling. Id. at 1996-97. And “absent clear evidence that the FDA would not have approved” the type of warning deemed necessary by the State claim, the Court was not willing to “conclude that it was impossible” for the manufacturer “to comply with both federal and state requirements.” Id. at 1198.
In light of the Supreme Court's decision in Wyeth, FDA has concluded that the position on preemption articulated in the preamble to the physician labeling rule, and subsequently referred to in the preambles of the other two rules cited previously in this document, cannot be justified under legal principles governing preemption. The codified provisions in these rules, however, do not include any statements about preemption and would not preempt State law beyond governing principles of preemption. FDA's conclusion about the regulatory preambles, therefore, does not affect the validity or operation of the codified provisions in these three final rules.
FDA also would like to clarify past preamble statements related to preemption resulting from certain express preemption provisions in the FD&C Act concerning nonprescription drugs and food labeling. Some preamble statements in regulations on nonprescription drugs contain the following language: “Currently, [Section 751(a) of the FD&C Act (21 U.S.C. 379r(a))] operates to preempt States from imposing requirements related to the regulation of nonprescription drug products (See section 751(b) through (e) of the act for the scope of the express preemption provision, the exemption procedures, and the exceptions to the provision) * * *. Although this final rule would have a preemptive effect, in that it would preclude States from issuing requirements related to these OTC * * * drug products that are different from or in addition to, or not otherwise identical with a requirement in the final rule, this preemptive effect is consistent with what Congress set forth in section 751 of the act. Section 751(a) of the act displaces both State legislative requirements and State common law duties * * *.”
(See, e.g., 74 FR 9759, March 6, 2009; 73 FR 6015, February 1, 2008; 72 FR 71769, December 19, 2007; 72 FR 14669, March 29, 2007; 72 FR 9849, March 6, 2007; 71 FR 43358, August 1, 2006). This language could be read to suggest that FDA does not read section 751 of the FD&C Act as a whole and gives more significance to some provisions, e.g., subsection 751(a), than others, e.g., subsection 751(e) (which makes clear that section 751 does not affect any action under a state's product liability law). FDA now clarifies that it does read section 751 of the FD&C Act as a whole, in that each subsection must be read together with the other subsections.
In addition, FDA is now clarifying preamble statements in regulations on food labeling that contain the following language: “Although this rule has a pre-emptive effect, in that it would preclude states from issuing any * * * requirements * * * that are not identical to those required by the final rule, this pre-emptive effect is consistent with what Congress set forth in Section 403A of the Act [21 U.S.C. 343-1].” (See, e.g., 74 FR 2443, January 15, 2009). Although this language reflects the statutory language in section 403A of the FD&C Act, as codified at 21 U.S.C. 343-1, it does not acknowledge Start Printed Page 61566the applicability limitation set forth in section 6(c)(2) of the Nutrition Labeling and Education Act (NLEA), which was not codified. Section 6(c)(2) of the NLEA provided that section 403A of the FD&C Act “shall not be construed to apply to any requirement respecting a statement on the labeling of food that provides for a warning concerning the safety of the food or component of the food” (Pub. L. 101-535, section 6, 104 Stat. 2353 (1990)). FDA clarifies that its past discussions of section 403A of the FD&C Act should have included the language of section 6(c)(2) of the NLEA.Start Signature
Dated: September 28, 2011.
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-25479 Filed 10-4-11; 8:45 am]
BILLING CODE 4160-01-P